
cyclosporine opht brand names and other generic formulations include:
haemoph b poly conj-tet tox-pf im brand names and other generic formulations include:
Acthib (pf) IM, Pentacel Acthib Component (pf) IM
cyclosporine opht and haemoph b poly conj-tet tox-pf im
cyclosporine opht decreases effects of haemoph b poly conj-tet tox-pf im by opposing drug effects. Taken together may increase the risk of infection.
cyclosporine opht and haemoph b poly conj-tet tox-pf im
cyclosporine opht decreases effects of haemoph b poly conj-tet tox-pf im by pharmacodynamic antagonism. If possible, complete all age-appropriate vaccinations at least 2 weeks before initiating immunosuppressant therapy. Patients vaccinated <14 days before starting immunosuppressive therapy or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued if immune competence has been restored. Longer waiting periods may be required for drugs that maintain their immunosuppressive effects for more than 3 months after discontinuation (eg, ocrelizumab).
Check for more interactions with the Drug Interaction Checker
Drug Interaction Categories
Contraindicated
Never use this combination of drugs because of high risk for dangerous interaction
Serious
Potential for serious interaction; regular monitoring by your doctor required or alternate medication may be needed
Significant
Potential for significant interaction (monitoring by your doctor is likely required)
Minor
Interaction is unlikely, minor, or nonsignificant